There are 2789 resources available
252P - Does the introduction of CDK4/6 inhibitors (CDKi) in first-line treatment of metastatic breast cancer (MBC) increase medical oncology workload?
Presenter: Claudia Noto
Session: ePoster Display
254P - Impact of palbociclib-dose reduction on survival: A retrospective cohort study
Presenter: Maria Luisa Romero Lagures
Session: ePoster Display
255P - Propreseer: A reliable, collaborative prognostic model for tamoxifen-resistance breast cancer
Presenter: Weiqi Nian
Session: ePoster Display
Resources:
Abstract
256P - PI3K mutation is associated with reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer
Presenter: Keechilat Pavithran
Session: ePoster Display
257P - Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
Presenter: Sibylle Loibl
Session: ePoster Display
100P - Characteristics and outcomes of patients (pts) with NTRK fusion-positive (NTRK+) metastatic / locally advanced (LA) solid tumours receiving non-TRK inhibitor (TRKi) standard of care (SoC), and prognostic value of NTRK fusions in clinical practice
Presenter: George Demetri
Session: ePoster Display
101P - The landscape of MET alterations in European cancer patients
Presenter: Jürgen Wolf
Session: ePoster Display
102P - NTRK test usage practices in Europe and Asia: Findings from a real-world study
Presenter: Kriti Jindal
Session: ePoster Display